Antisoma plc

I was once on a teleconference for middle managers of one big UK pharmaceutical company that was merging with another while the chairman of R&D explained the competitive reasons why neither company co

I was unfortunately and publicly proved right about two events last week. Unfortunate, because neither was a positive outcome. On the Brexit vote, I was right partly for the wrong reason since I guess

In life sciences, big share price movements occur in response to merger and acquisition (M&A) activity, clinical trial results and regulatory events. Actual, rather than rumoured M&A is the panacea fo

It must have been a tense board meeting. Starting at 9.00 p.m. UK time on Thursday 12 November, Oxford Immunotec's bankers, investors and management convened to push a small, non-US-domiciled diagnost